Company intelligence / Profile preview
Hyloris
Liège, Belgiumhyloris.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
Hyloris has two partnered commercial-stage products—Sotalol IV for atrial fibrillation and Maxigesic® IV for post-operative pain. The company also has a pipeline of value-added medicines using the FDA’s 505(b)(2) pathway to reduce development time and risk. A notable late-stage asset includes tranexamic acid oral solution in Phase 3 trials for bleeding prevention during dental procedures in anticoagulated patients
- Therapeutic areas
- HematologyNeurologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Commercialization partners for Sotalol IV and Maxigesic® IV; specific partner names not publicly detailed.
Beyond the preview
Go deeper on Hyloris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyloris.